The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS): A systematic review and meta-analysis.
 
Abdulrahman Alhajahjeh
No Relationships to Disclose
 
Naira Woite
No Relationships to Disclose
 
Alyssa Grimshaw
No Relationships to Disclose
 
Benjamin Rolles
No Relationships to Disclose
 
Maximilian Stahl
Consulting or Advisory Role - Boston Consulting Group; Clinical Care Options; Curis Oncology; GlaxoSmithKline; Haymarket; Kymera; Novartis; Sierra Oncology
 
Tariq Kewan
No Relationships to Disclose
 
Nikolai Podoltsev
Consulting or Advisory Role - Abbvie; Aptose Biosciences; Blueprint Medicines; Constellation Pharmaceuticals; CTI BioPharma Corp; Incyte; Karyopharm Therapeutics; Novartis; PhramaEssentia
Research Funding - AI Therapeutics (Inst); Aptos Biosciences (Inst); Arog (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Jazz Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Karyophram Therapeutics (Inst); Pfizer (Inst); PharmaEssentia (Inst); Samus Therapeutics (Inst); Sunesis Pharmaceuticals (Inst)
Other Relationship - Cogent Biosciences
 
Jessica Stempel
Consulting or Advisory Role - Sobi
 
Lourdes Mendez
Consulting or Advisory Role - Inventiva Pharma; Rigel
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Jan Philipp Bewersdorf
No Relationships to Disclose